Author: Zhou Hui
Producer: Insight IPO
Shanghai Stock Exchange & Shenzhen Stock Exchange
IPO listing
November 27 - December 3Shanghai Stock ExchangeThere is a science and technology innovation board1 homeThe company went publicShenzhen Stock ExchangeGEM has2The company went public
Data**: publicly available information; Chart Making: Insight IPO 1Jingyi Equipment: Mainly engaged in the research and development, production and sales of semiconductor special equipment, the main products include semiconductor special temperature control equipment (chiller), semiconductor special process waste gas treatment equipment (local scrubber) and wafer transfer equipment (sorter), which closed up 74 on the first day of listing59%, as of December 4** reported 5455 yuan shares, compared with the issue price of 3195 yuan shares rose 7074%。
Data**: publicly available information; Chart Making: Insight IPO 1Sitek: Mainly engaged in the research and development, production, sales and value-added services of machine vision inspection equipment, it closed up 187 on the first day of listing47%, as of December 4** reported 5208 yuan shares, compared with the issue price of 2323 yuan shares rose 12419%。
2.China Machinery Certification: A national comprehensive service organization for third-party certification, inspection and testing of vehicles and machinery and equipment, closed up 191 on the first day of listing74%, as of December 4** reported 4744 yuan shares, compared with the issue price of 1682 yuan, the stock rose 18205%。
Adoption of the Listing Committee Review Meeting
November 27 - December 3Shanghai Stock ExchangeShenzhen Stock ExchangeNone of the companies have ever met.
Submission of listing application
November 27 - December 3Shanghai Stock ExchangeShenzhen Stock ExchangeNone of the companies submitted listing applications.
Hong Kong Stock Exchange
IPO listing
November 27-December 3, Hong Kong Stock ExchangeNoneThe company went public
IPO Offering
From November 27th to December 3rd, the Hong Kong Stock Exchange will have it6 homesIPO, of which 4 completed the IPO during the week.
Data**: publicly available information; Chart Making: Insight IPO 1Synergy Hydrogen Energy: A hydrogen fuel cell company focusing on the research, development, production and sales of hydrogen fuel cell stacks and hydrogen fuel cell systems.
2.K Cash Group: A licensed money lender in Hong Kong focused on providing unsecured loans through fintech.
3.Dekang Agriculture and Animal Husbandry: Livestock and poultry breeding enterprises, focusing on the breeding and breeding of pigs and yellow-feathered broilers.
4.Shenghui Cleaning: Environmental cleaning and maintenance service provider, providing property cleaning services.
5.Fullview China Holdings: The largest producer of potted vegetable agricultural products in Shandong Province.
6.Bird's Nest House: Committed to R&D, production and sales of high-quality modern bird's nest products.
Passed the listing hearing
From November 27th to December 3rd, the Hong Kong Stock Exchange will have it5 homesThe company passed the hearing.
Data**: publicly available information; Chart Making: Insight IPO 1Jihai Resources: A leading exploration, mining and processing company located in Yantai City, Shandong Province, China.
2.Fullview China Holdings: The largest producer of potted vegetable agricultural products in Shandong Province.
3.Ruipu Lanjun: A lithium-ion battery manufacturer, focusing on the R&D, manufacturing and sales of lithium-ion power battery products and energy storage battery products.
4.UBTECH: A robotics company dedicated to the design, production, commercialization, sales and marketing, and R&D of intelligent service robots and intelligent service robot solutions.
5.Suteng Juchuang: A lidar company that provides lidar products and solutions.
Submission of listing application
From November 27th to December 3rd, the Hong Kong Stock Exchange will have it4 homesThe company submitted an application for listing on the Main Board.
Data**: publicly available information; Chart Making: Insight IPO 1Bright International: A property developer focusing on the revitalization of non-performing loan collateral properties for sale and rental.
2.XtalPi: An innovative R&D platform based on quantum physics, powered by artificial intelligence and driven by robots.
3.Clinical-stage ophthalmic biotechnology company.
4.Mobvoi: It mainly provides AI-generated content (AIGC) solutions, AI enterprise solutions, smart devices and accessories with generative AI and voice interaction technology as its core business.
Haohui International disclosed its prospectus on November 28
It is planned to land on the main board of the Hong Kong Stock Exchange
On November 28, Haohui International Holdings*** referred to as Haohui International) submitted a prospectus to the Hong Kong Stock Exchange to be listed on the main board IPO, with Dongxing ** (Hong Kong) as its sole sponsor.
According to the prospectus, the issuance of Haohui International will be used to develop existing property projects (i.e., Enping plot and Wanrui Ideal Huafu) construction and related costs, land or project acquisition, and general working capital, and the specific amount raised is not disclosed.
Bright International is a property developer focusing on the revitalization of non-performing loan collateral properties for sale and rental. Unlike traditional real estate developers who typically increase their land bank through the listing** process, Bright International focuses on identifying and acquiring mortgaged properties with non-performing loans. Bright International acquires properties secured by non-performing loans through asset management companies, judicial auctions and acquisitions with or from property developers.
As at the valuation date, Brilliance International had a total of 10 property development projects in various stages of development, which were located in Foshan, Yangchun and Enping in Guangdong Province and Daqing in Heilongjiang Province. As at the valuation date, Brilliance International's total land bank was approximately 49120,000 sqm, comprising the gross unsold and pre-sold gross floor area of completed properties and the lettable gross floor area held for investment11570,000 square meters; The planned construction area under development is 15150,000 square meters; and an estimated gross floor area held for future development22390,000 square meters.
In terms of financial data, from 2020 to 2022, Haohui International achieved operating income of 11.5 billion yuan, 18.2 billion yuan, 28.6 billion yuan, and the revenue growth in 2021 and 2022 will be respectively. 75%；The net profit was 243230,000 yuan, 454940,000 yuan, 657100,000 yuan, the net profit growth in 2021 and 2022 will be respectively. 44%。
From January to June 2023, Haohui International's operating income was 31 billion yuan, with a net profit of 462080,000 yuan.
XtalPi disclosed its prospectus on November 30
It is planned to land on the main board of the Hong Kong Stock Exchange
Nov. 30, Quantumpharm IncXtalPi submitted a prospectus to the Hong Kong Stock Exchange for an IPO on the Main Board, with CITIC ** as its sole sponsor.
According to the prospectus, the issuance of XtalPi will be used to continuously improve its R&D capabilities and solution provision capabilities, enhance commercialization capabilities, working capital and general corporate purposes, and the specific amount raised is not disclosed.
XtalPi is a world-leading innovative R&D platform based on quantum physics, powered by artificial intelligence and driven by robots. Combining first-principles computing based on quantum physics, advanced artificial intelligence, high-performance cloud computing, and scalable and standardized robotic automation, we provide drug and materials science R&D solutions and services to global conglomerates and innovative companies in industries such as pharmaceuticals and materials science, including agricultural technology, energy and emerging chemicals, and cosmetics.
The business mainly includes drug discovery solutions (providing solutions that span different modules in the whole process of drug discovery and research); and intelligent automation solutions (mainly including solid-state R&D services and automated chemical synthesis services).
In terms of financial data, from 2020 to 2022, XtalPi achieved operating income of 3,56360,000 yuan, 627990,000 yuan, 13.3 billion yuan, and the revenue growth in 2021 and 2022 will be respectively. 35%；Adjusted net income was -12.2 billion yuan, -27.1 billion yuan, -43.7 billion yuan.
From January to June 2023, XtalPi's operating revenue was 7,99670,000 yuan, adjusted net profit of -35.8 billion yuan.
On November 30, the company disclosed its prospectus
It is planned to land on the main board of the Hong Kong Stock Exchange
November 30, Cloudbreak Pharma Inc(hereinafter referred to as "Dial Kang Vision Cloud") submitted a prospectus to the Hong Kong Stock Exchange to be listed on the main board of the IPO, with UBS Group, CCB International and Huatai International as its joint sponsors.
According to the prospectus, the issuance will be used for the continuous clinical research and development activities of the core product CBT-001 (including the costs and expenses of R&D personnel and R&D activities), as well as the funds required for registration, filing and post-approval research; ongoing clinical research and development activities, including the costs and expenses of R&D personnel and R&D activities, as well as funding required for the registration and filing of the core product CBT-009; ongoing clinical research and development activities (including costs and expenses of R&D personnel and activities) for other clinical-stage drug candidates (i.e., CBT-006 and CBT-004) and preclinical stage drug candidates (i.e., CBT-007, CBT-145 and CBT-011) and funding required for registration filing; Funding for production facilities and commercialization activities; Working capital and other general corporate purposes. The exact amount raised was not disclosed.
We are an innovation-driven, clinical-stage ophthalmic biotechnology company dedicated to the development of novel and differentiated**. Committed to the in-house discovery, development and commercialization of first-in-class and best-in-class ophthalmology** to address unmet medical needs worldwide.
We have built a broad and innovative pipeline of seven drug candidates covering major diseases in the front and back of the eye, including four clinical-stage drug candidates (i.e., CBT-001, CBT-009, CBT-006 and CBT-004) and three pre-clinical stage drug candidates (i.e., CBT-007, CBT-145 and CBT-011). Once approved, CBT-001 and CBT-004 are expected to be world-class first-in-class drugs for pterygium and vascularized palpebral fissures, respectively.
In terms of financial data, from January to June 2021, 2022 and 2023, the company only generated 68 other revenues$80,000, $47$10,000 and $46$30,000; The net profit was -3539$80,000, -6683$80,000 and -5625$70,000.
Mobvoi disclosed its prospectus on December 1
It is planned to land on the main board of the Hong Kong Stock Exchange
On December 1, Mobvoi submitted a prospectus to the Hong Kong Stock Exchange to be listed on the main board of the IPO, with CICC and CMB International as its joint sponsors.
According to the prospectus, Mobvoi will be used to continuously improve modeling technology for model training, through the introduction of excellent technology and talents in the next few years, vertical optimization of the underlying basic model, and improvement of the existing program algorithm of the solution; solution development and marketing; pursue strategic alliances, investments and acquisitions to implement long-term growth strategies for solution development; Working capital and general corporate purposes. The exact amount raised was not disclosed.
Mobvoi: It mainly provides AI-generated content (AIGC) solutions, AI enterprise solutions, smart devices and accessories with generative AI and voice interaction technology as its core business.
According to the CIC report, in terms of revenue recognized in 2022, Mobvoi's market share in China's AI speech technology and natural language processing software solutions is 14%, ranking third.
On the other hand, in the fast-growing AIGC field, Mobvoi is one of the market players in Asia that can build its own large model "Sequence Monkey", which has multimodal generation capabilities and can understand and generate human-like text, audio, images, and **.
In terms of financial data, from 2020 to 2022, Mobvoi achieved operating income of 26.5 billion yuan, 39.8 billion yuan, 50 billion yuan, the revenue growth in 2021 and 2022 will be respectively. 70%；The net profit was 561460,000 yuan, -27.6 billion yuan, -67 billion yuan.
From January to June 2023, Mobvoi's operating income will be 26.2 billion yuan, net profit of -2$1.8 billion.
Mobvoi submitted a prospectus to the Hong Kong Stock Exchange on May 30, 2023, which is now invalid.
Readers are advised that this article is based on public information or relevant content provided by interviewees, and the author of Insight IPO and article does not guarantee the completeness and accuracy of relevant information. In any event, the content of this article does not constitute investment advice. The market is risky, and investment needs to be cautious!No **, plagiarism without permission!